These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 31193016)

  • 1. The Impact of Pre-existing Immunity on the Non-clinical Pharmacodynamics of AAV5-Based Gene Therapy.
    Long BR; Sandza K; Holcomb J; Crockett L; Hayes GM; Arens J; Fonck C; Tsuruda LS; Schweighardt B; O'Neill CA; Zoog S; Vettermann C
    Mol Ther Methods Clin Dev; 2019 Jun; 13():440-452. PubMed ID: 31193016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A.
    Long BR; Veron P; Kuranda K; Hardet R; Mitchell N; Hayes GM; Wong WY; Lau K; Li M; Hock MB; Zoog SJ; Vettermann C; Mingozzi F; Schweighardt B
    Mol Ther; 2021 Feb; 29(2):597-610. PubMed ID: 33309883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prednisolone Does Not Regulate Factor VIII Expression in Mice Receiving AAV5-hFVIII-SQ: Valoctocogene Roxaparvovec.
    Zhang L; Handyside B; Murphy R; Sihn CR; Xie L; Vitelli C; Harmon D; Sisó S; Liu S; Bullens S; Bunting S; Fong S
    Mol Ther Methods Clin Dev; 2020 Jun; 17():13-20. PubMed ID: 31890737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular analysis of AAV5-hFVIII-SQ vector-genome-processing kinetics in transduced mouse and nonhuman primate livers.
    Sihn CR; Handyside B; Liu S; Zhang L; Murphy R; Yates B; Xie L; Torres R; Russell CB; O'Neill CA; Pungor E; Bunting S; Fong S
    Mol Ther Methods Clin Dev; 2022 Mar; 24():142-153. PubMed ID: 35036471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of ER Stress by an AAV5 BDD FVIII Construct Is Dependent on the Strength of the Hepatic-Specific Promoter.
    Fong S; Handyside B; Sihn CR; Liu S; Zhang L; Xie L; Murphy R; Galicia N; Yates B; Minto WC; Vitelli C; Harmon D; Ru Y; Yu GK; Escher C; Vowinckel J; Woloszynek J; Akeefe H; Mahimkar R; Bullens S; Bunting S
    Mol Ther Methods Clin Dev; 2020 Sep; 18():620-630. PubMed ID: 32775496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultra-sensitive AAV capsid detection by immunocapture-based qPCR following factor VIII gene transfer.
    Sandza K; Clark A; Koziol E; Akeefe H; Yang F; Holcomb J; Patton K; Hammon K; Mitchell N; Wong WY; Zoog SJ; Kim B; Henshaw J; Vettermann C
    Gene Ther; 2022 Feb; 29(1-2):94-105. PubMed ID: 34421119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy.
    Rosen S; Tiefenbacher S; Robinson M; Huang M; Srimani J; Mackenzie D; Christianson T; Pasi KJ; Rangarajan S; Symington E; Giermasz A; Pierce GF; Kim B; Zoog SJ; Vettermann C
    Blood; 2020 Nov; 136(22):2524-2534. PubMed ID: 32915950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenovirus-associated antibodies in UK cohort of hemophilia patients: A seroprevalence study of the presence of adenovirus-associated virus vector-serotypes AAV5 and AAV8 neutralizing activity and antibodies in patients with hemophilia A.
    Stanford S; Pink R; Creagh D; Clark A; Lowe G; Curry N; Pasi J; Perry D; Fong S; Hayes G; Chandrakumaran K; Rangarajan S
    Res Pract Thromb Haemost; 2019 Apr; 3(2):261-267. PubMed ID: 31011710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A.
    Klamroth R; Hayes G; Andreeva T; Gregg K; Suzuki T; Mitha IH; Hardesty B; Shima M; Pollock T; Slev P; Oldenburg J; Ozelo MC; Stieltjes N; Castet SM; Mahlangu J; Peyvandi F; Kazmi R; Schved JF; Leavitt AD; Callaghan M; Pan-Petesch B; Quon DV; Andrews J; Trinh A; Li M; Wong WY
    Hum Gene Ther; 2022 Apr; 33(7-8):432-441. PubMed ID: 35156839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.
    Ozelo MC; Mahlangu J; Pasi KJ; Giermasz A; Leavitt AD; Laffan M; Symington E; Quon DV; Wang JD; Peerlinck K; Pipe SW; Madan B; Key NS; Pierce GF; O'Mahony B; Kaczmarek R; Henshaw J; Lawal A; Jayaram K; Huang M; Yang X; Wong WY; Kim B;
    N Engl J Med; 2022 Mar; 386(11):1013-1025. PubMed ID: 35294811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.
    Pasi KJ; Rangarajan S; Mitchell N; Lester W; Symington E; Madan B; Laffan M; Russell CB; Li M; Pierce GF; Wong WY
    N Engl J Med; 2020 Jan; 382(1):29-40. PubMed ID: 31893514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome.
    Aronson SJ; Veron P; Collaud F; Hubert A; Delahais V; Honnet G; de Knegt RJ; Junge N; Baumann U; Di Giorgio A; D'Antiga L; Ginocchio VM; Brunetti-Pierri N; Labrune P; Beuers U; Bosma PJ; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1297-1305. PubMed ID: 31502485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs.
    Majowicz A; Nijmeijer B; Lampen MH; Spronck L; de Haan M; Petry H; van Deventer SJ; Meyer C; Tangelder M; Ferreira V
    Mol Ther Methods Clin Dev; 2019 Sep; 14():27-36. PubMed ID: 31276009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A.
    Fong S; Yates B; Sihn CR; Mattis AN; Mitchell N; Liu S; Russell CB; Kim B; Lawal A; Rangarajan S; Lester W; Bunting S; Pierce GF; Pasi KJ; Wong WY
    Nat Med; 2022 Apr; 28(4):789-797. PubMed ID: 35411075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
    Sun J; Hua B; Chen X; Samulski RJ; Li C
    Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of germline transmission in male mice following a single intravenous administration of AAV5-hFVIII-SQ gene therapy.
    Fonck C; Su C; Arens J; Koziol E; Srimani J; Henshaw J; Van Tuyl A; Chandra S; Vettermann C; O'Neill CA
    Gene Ther; 2023 Aug; 30(7-8):581-586. PubMed ID: 35132205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of
    Liu S; Razon L; Ritchie O; Sihn CR; Handyside B; Berguig G; Woloszynek J; Zhang L; Batty P; Lillicrap D; Agrawal V; Cortesio C; Gebretsadik K; Akeefe H; Colosi P; Kim B; Bunting S; Fong S
    Mol Ther Methods Clin Dev; 2022 Sep; 26():61-71. PubMed ID: 35782594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Young mice administered adult doses of AAV5-hFVIII-SQ achieve therapeutic factor VIII expression into adulthood.
    Zhang L; Yates B; Murphy R; Liu S; Xie L; Handyside B; Sihn CR; Bouwman T; Galicia N; Tan D; Fonck C; Arens J; Clark A; Zhang W; Chandra S; Srimani J; Holcomb J; Van Tuyl A; Henshaw J; Vettermann C; Siso S; Su C; Bullens S; Bunting S; O'Neill C; Fong S
    Mol Ther Methods Clin Dev; 2022 Sep; 26():519-531. PubMed ID: 36092364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategy to detect pre-existing immunity to AAV gene therapy.
    Falese L; Sandza K; Yates B; Triffault S; Gangar S; Long B; Tsuruda L; Carter B; Vettermann C; Zoog SJ; Fong S
    Gene Ther; 2017 Dec; 24(12):768-778. PubMed ID: 29106404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction.
    Fitzpatrick Z; Leborgne C; Barbon E; Masat E; Ronzitti G; van Wittenberghe L; Vignaud A; Collaud F; Charles S; Simon Sola M; Jouen F; Boyer O; Mingozzi F
    Mol Ther Methods Clin Dev; 2018 Jun; 9():119-129. PubMed ID: 29766022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.